Increase in Total Net Revenue
Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year period, primarily reflecting higher U.S. sales.
U.S. Market Performance
Net product revenue in the U.S. was $40.9 million, an increase of $10.3 million or 34%, driven by an increase in net selling price and volume.
Successful Partnership with Recordati
The transition to a fully partnered commercial model in Europe is progressing well, with sustained momentum and growth in demand across all commercialized European markets.
Cost Savings and Restructuring
SG&A expenses were reduced by $17.2 million or 47% over the prior year period, indicating the benefits of organizational restructuring.
FDA Labeling Update on Fenofibrates
The FDA revised the labeling of fenofibrates to include a statement on the lack of cardiovascular benefit, which may shift clinical practice towards proven therapies like VASCEPA.